DE69410193T2 - Neue verbindungen mit blutplättchenaggregationshemmender aktivität - Google Patents

Neue verbindungen mit blutplättchenaggregationshemmender aktivität

Info

Publication number
DE69410193T2
DE69410193T2 DE69410193T DE69410193T DE69410193T2 DE 69410193 T2 DE69410193 T2 DE 69410193T2 DE 69410193 T DE69410193 T DE 69410193T DE 69410193 T DE69410193 T DE 69410193T DE 69410193 T2 DE69410193 T2 DE 69410193T2
Authority
DE
Germany
Prior art keywords
functional group
group
general formula
compound
designated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69410193T
Other languages
German (de)
English (en)
Other versions
DE69410193D1 (de
Inventor
Kenji Pharmaceutical Research Cente Kouhoku-Ku Yokohama-Shi Kanagawa 222 Asai
Emiko Pharmaceutical Research Cente Kouhoku-Ku Yokohama-Shi Kanagawa 222 Hatsushiba
Hiroyuki Pharmaceutical Research Center Kouhoku-Ku Yokohama-Shi Kanagawa 222 Iida
Midori Pharmaceutical Research Center Kouhoku-Ku Yokohama-Shi Kanagawa 222 Ishikawa
Yasuko Pharmaceutical Research Center Kouhoku-Ku Yokohama-Shi Kanagawa 222 Isomura
Kiyoaki Pharmaceutical Research Center Kouhoku-Ku Yokohama-Shi Kanagawa 222 Katano
Mami Pharmaceutical Research Center Kouhoku-Ku Yokohama-Shi Kanagawa 222 Kawaguchi
Tomoaki Pharmaceutical Research Center Kouhoku-Ku Yokohama-Shi Kanagawa 222 Miura
Shokichi Pharmaceutical Research Center Kouhoku-Ku Yokohama-Shi Kanagawa 222 Ohuchi
Masaro Pharmaceutical Research Center Kouhoku-Ku Yokohama-Shi Kanagawa 222 Shimizu
Eiki Pharmaceutical Research Center Kouhoku-Ku Yokohama-Shi Kanagawa 222 Shitara
Takashi Pharmaceutical Research Center Kouhoku-Ku Yokohama-Shi Kanagawa 222 Tsuruoka
Kazue Pharmaceutical Research Cente Kouhoku-Ku Yokohama-Shi Kanagawa 222 Yaegashi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Meiji Seika Kaisha Ltd
Original Assignee
Meiji Seika Kaisha Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Meiji Seika Kaisha Ltd filed Critical Meiji Seika Kaisha Ltd
Publication of DE69410193D1 publication Critical patent/DE69410193D1/de
Application granted granted Critical
Publication of DE69410193T2 publication Critical patent/DE69410193T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/24—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C257/00—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
    • C07C257/10—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines
    • C07C257/16—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines having carbon atoms of amidino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C257/00—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
    • C07C257/10—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines
    • C07C257/18—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines having carbon atoms of amidino groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C279/14—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/16—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/10—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D263/14—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Hydrogenated Pyridines (AREA)
DE69410193T 1993-03-17 1994-03-17 Neue verbindungen mit blutplättchenaggregationshemmender aktivität Expired - Fee Related DE69410193T2 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP5746393 1993-03-17
JP8214593 1993-04-08
JP26527393 1993-10-22
PCT/JP1994/000437 WO1994021599A1 (fr) 1993-03-17 1994-03-17 Nouveau compose a activite inhibitrice de l'agregation des plaquettes

Publications (2)

Publication Number Publication Date
DE69410193D1 DE69410193D1 (de) 1998-06-18
DE69410193T2 true DE69410193T2 (de) 1998-09-03

Family

ID=27296266

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69410193T Expired - Fee Related DE69410193T2 (de) 1993-03-17 1994-03-17 Neue verbindungen mit blutplättchenaggregationshemmender aktivität

Country Status (15)

Country Link
US (2) US5594004A (en:Method)
EP (1) EP0641770B1 (en:Method)
JP (1) JP2680196B2 (en:Method)
KR (1) KR100196563B1 (en:Method)
CN (1) CN1045084C (en:Method)
AT (1) ATE166047T1 (en:Method)
AU (1) AU688756B2 (en:Method)
CA (1) CA2136007C (en:Method)
DE (1) DE69410193T2 (en:Method)
DK (1) DK0641770T3 (en:Method)
ES (1) ES2117264T3 (en:Method)
NO (1) NO308607B1 (en:Method)
NZ (1) NZ262768A (en:Method)
TW (1) TW269687B (en:Method)
WO (1) WO1994021599A1 (en:Method)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI0656348T1 (en) * 1993-12-03 2000-08-31 F. Hoffmann-La Roche Ag Aceric acid derivatives as medicaments
WO1997036887A1 (en) * 1996-03-29 1997-10-09 Meiji Seika Kaisha, Ltd. Novel heterocyclic compounds having platelet aggregation inhibitory effects
US5792761A (en) * 1996-08-12 1998-08-11 Merck & Co., Inc. Thrombin inhibitors
EP1209152A4 (en) 1999-08-05 2003-03-12 Meiji Seika Kaisha OMEGA-AMINO-ALPHA-HYDROXY-CARBONIC ACID DERIVATIVES WITH AN INTEGRIN ALPHA V BETA ANTAGONISM
TWI290136B (en) 2000-04-05 2007-11-21 Daiichi Seiyaku Co Ethylenediamine derivatives
PL206138B1 (pl) 2000-12-25 2010-07-30 Daiichi Sankyo Company Limiteddaiichi Sankyo Company Limited Kompozycja farmaceutyczna zawierająca aspirynę oraz zestaw i zastosowanie składników kompozycji
WO2003000657A1 (en) 2001-06-20 2003-01-03 Daiichi Pharmaceutical Co., Ltd. Diamine derivatives
EP2404899A1 (en) * 2004-02-25 2012-01-11 Astellas Pharma Inc. Contrast medium for thrombus detection
DK1778243T3 (da) * 2004-06-30 2013-02-04 Athersys Inc Substituerede azepinderivater som serotoninreceptormodulatorer
EP1773370A1 (en) * 2004-07-07 2007-04-18 Medicure International Inc. Combination therapies employing platelet aggregation drugs
US7459468B2 (en) * 2004-10-28 2008-12-02 Medicure International, Inc. Aryl sulfonic pyridoxines as antiplatelet agents
WO2006050598A1 (en) 2004-10-28 2006-05-18 Medicure International Inc. Dual antiplatelet/anticoagulant pyridoxine analogs
US20060094749A1 (en) * 2004-10-28 2006-05-04 Medicure International Inc. Substituted pyridoxines as anti-platelet agents
WO2012104866A1 (en) 2011-01-31 2012-08-09 Council Of Scientific & Industrial Research Chiral 1-(4-methylphenylmethyl)-5-oxo-{n-[(3-t-butoxycarbonyl- aminomethyl)]-piperidin-1-yl}-pyrrolidine-2-carboxamides as inhibitors of collagen induced platelet activation and adhesion
CN103351359B (zh) * 2013-07-25 2015-02-25 郑桂富 一种3-苯甲基-5-(2-羟乙基)-4-甲基噻唑啉氯的合成方法
CN108602837B (zh) * 2015-09-04 2022-02-11 新丰制药株式会社 具有抑制血小板聚集效果的化合物及其盐、以及包含其的用于预防或治疗血栓性疾病的组合物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8528398D0 (en) * 1985-11-19 1985-12-24 Glaxo Group Ltd Chemical compounds
WO1988010113A1 (en) * 1987-06-15 1988-12-29 Iraj Lalezari Compound, composition and method for the reduction of lipids the modification of the affinity of hemoglobin for oxygen and the prevention of platelet aggregation
US4921997A (en) * 1988-06-15 1990-05-01 Montefiore Medical Center Method of synthesis and novel compounds for pharmaceutical uses
US5084466A (en) * 1989-01-31 1992-01-28 Hoffmann-La Roche Inc. Novel carboxamide pyridine compounds which have useful pharmaceutical utility
DE4010536A1 (de) * 1990-04-02 1991-10-10 Boehringer Mannheim Gmbh Pharmazeutische waessrige loesung von 4-(2-(benzolsulfonylamino)-ethyl)-phenoxyessigsaeure
PH31566A (en) * 1990-10-10 1998-11-03 Schering Corp Pyridine and pyridine n-oxide derivatives for diaryl methyl piperidines or piperazines and compositions and methods of use thereof.
JP2503797B2 (ja) 1991-03-11 1996-06-05 株式会社セガ・エンタープライゼス 熱変色遊戯機
US5220050A (en) * 1991-05-17 1993-06-15 G. D. Searle & Co. Peptide mimetic compounds useful as platelet aggregation inhibitors

Also Published As

Publication number Publication date
DE69410193D1 (de) 1998-06-18
EP0641770B1 (en) 1998-05-13
WO1994021599A1 (fr) 1994-09-29
US5698692A (en) 1997-12-16
NO944371D0 (no) 1994-11-16
EP0641770A1 (en) 1995-03-08
NZ262768A (en) 1997-03-24
CA2136007A1 (en) 1994-09-29
ATE166047T1 (de) 1998-05-15
CA2136007C (en) 1999-12-14
EP0641770A4 (en) 1995-06-28
NO944371L (no) 1995-01-13
CN1107277A (zh) 1995-08-23
ES2117264T3 (es) 1998-08-01
NO308607B1 (no) 2000-10-02
DK0641770T3 (da) 1998-06-02
US5594004A (en) 1997-01-14
AU688756B2 (en) 1998-03-19
TW269687B (en:Method) 1996-02-01
AU6263894A (en) 1994-10-11
KR100196563B1 (ko) 1999-06-15
CN1045084C (zh) 1999-09-15
KR950701615A (ko) 1995-04-28
JP2680196B2 (ja) 1997-11-19

Similar Documents

Publication Publication Date Title
DE3888568T2 (de) Menschliche peptidische Hemmungsstoffe von Leukozyten-Elastase (HLE).
DE69232003T2 (de) Benzanilidderivate als 5-HT1D-Antagonisten
DE60208068T2 (de) Benzamidinderivate als antagonisten von orexinrezeptoren
DE69111619T2 (de) 1,4-benzothiazedinderivat.
EP0749429B1 (de) 3,5-disubstituierte und 3,4,5-trisubstituierte 2-isoxazoline und isoxazole, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE1595915C3 (de) Pyrrolidinderivate
DE69021472T2 (de) Pyrazolderivate, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zusammenstellung.
DE69717268T2 (de) M-amidinophenyl-analoga als faktor-xa-inhibitoren
DE69408988T2 (de) Aminosäurederivate als no-synthaseinhibitoren
DE3218584A1 (de) 1,2-diaminocyclobuten-3,4-dione, verfahren zu deren herstellung und pharmazeutische mittel, die diese verbindungen enthalten
DE69222280T2 (de) Kondensierte Benzeoxyessigsäurederivate
US5698692A (en) Compound with platelet aggregation inhibitor activity
DE4219158A1 (de) Biphenylderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
JPH01261381A (ja) オキサ（チア）ジアゾール誘導体、その製造方法及び殺ダニ剤
DE69102816T2 (de) Piperdinyloxy- und Chinindidinyloxy- isoxazol- Derivate, ihre Herstellung und ihre therapeutische Verwendung.
DE68911699T2 (de) Diamin-Verbindungen.
JPWO1994021599A1 (ja) 血小板凝集阻害作用を有する新規化合物
LU82000A1 (de) Neue thiazolylmethylthioderivate,verfahren zu deren herstellung und arzneimittel
DE69310904T2 (de) Verbrückte bis-aryl-carbinol-derivate, zusammensetzungen und ihre verwendung
DE2842100A1 (de) Omega -thiopropionamide, verfahren zu ihrer herstellung und sie enthaltende arzneimittel
JPH0649047A (ja) フェニルカルボキサミドイソオキサゾールの新誘導体及びそれらの塩類、それらの製造法及びこの製造法の新規な中間体、それらの薬剤としての用途並びにそれらを含有する製薬組成物
DE69405815T2 (de) Acylharnstoffe
CH629204A5 (de) Verfahren zur herstellung von 4-hydroxy-3-(5-methyl-3-isoxazolylcarbamoyl)-2-methyl-2h-1,2-benzothiazin-1,1-dioxyd.
DE2362754A1 (de) Cyclopropylmethylamine, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
EP1121349B1 (de) Substituierte thiadiazolsulfonamide als interleukin-1-beta-hemmer

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: JUNG, SCHIRDEWAHN, GRUENBERG, SCHNEIDER PATENTANWAELTE

8328 Change in the person/name/address of the agent

Representative=s name: ADVOTEC. PATENT- UND RECHTSANWAELTE, 80538 MUENCHE

8339 Ceased/non-payment of the annual fee